Zoetis Inc. or BioMarin Pharmaceutical Inc.: Who Manages SG&A Costs Better?

Zoetis vs. BioMarin: A Decade of SG&A Cost Management

__timestampBioMarin Pharmaceutical Inc.Zoetis Inc.
Wednesday, January 1, 20143021560001643000000
Thursday, January 1, 20154022710001532000000
Friday, January 1, 20164765930001364000000
Sunday, January 1, 20175543360001334000000
Monday, January 1, 20186043530001484000000
Tuesday, January 1, 20196809240001638000000
Wednesday, January 1, 20207376690001726000000
Friday, January 1, 20217593750002001000000
Saturday, January 1, 20228540090002009000000
Sunday, January 1, 20239373000002151000000
Monday, January 1, 202410090250002318000000
Loading chart...

Unleashing insights

Who Manages SG&A Costs Better: Zoetis Inc. or BioMarin Pharmaceutical Inc.?

In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Zoetis Inc. and BioMarin Pharmaceutical Inc. have shown distinct approaches to handling these costs. From 2014 to 2023, Zoetis Inc. consistently reported higher SG&A expenses, peaking at approximately $2.15 billion in 2023. In contrast, BioMarin's expenses grew steadily, reaching around $937 million in the same year. Despite Zoetis's higher absolute costs, their expenses as a percentage of revenue have remained relatively stable, indicating efficient cost management. Meanwhile, BioMarin's expenses have increased by over 200% since 2014, reflecting their aggressive growth strategy. This data provides a fascinating insight into how these two industry leaders balance cost management with growth ambitions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025